Maple Grove, MN – May 7, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of Doxazosin Tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg (the branded product, Cardura® (doxazosin mesylate tablets)*). The product was approved by the U.S. Food and Drug Administration (FDA) on April 17, 2018.
Doxazosin tablets 1 mg, 2 mg, 4 mg and 8 mg are prescribed for signs and symptoms of Benign Prostatic Hyperplasia (BPH), and treatment of Hypertension in the U.S.
The doxazosin tablet market had U.S. sales of approximately $51.2 million for the 12 months ending January, 2018 according to IQVIA.
* Cardura® is a registered trademark of Pfizer Inc.
About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that has strived to deliver quality, affordable generic medications for nearly a century. In June 2017, Upsher-Smith was acquired by Sawai Pharmaceutical Co., Ltd., a large publicly traded generics company in Japan that had been seeking entry into the U.S. market. Upsher-Smith and Sawai share a strikingly similar family history and hold many of the same cherished goals and values— most importantly, the philosophy of always putting patients first. Upsher-Smith will continue to do those things it does best, which is provide a consistent supply of quality, affordable medications and invest in its historically strong industry relationships. Ultimately, Upsher-Smith believes the acquisition by Sawai represents a tremendous opportunity to leverage each company for growth worldwide and embark together on an exciting new chapter in generics. For more information, visit https://www.upsher-smith.com.